[Adjuvant chemotherapy in breast cancer. International perspective]

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)].

Cancer treatment reviews·2025

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period.

Breast (Edinburgh, Scotland)·2025

Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.

Tumori·2026

Survival of carcinoid lung neuroendocrine tumours after surgical resection: A retrospective audit of 633 cases over 26 years.

Tumori·2026

Analysing workflows in radiation oncology: A process mining approach to identify treatment process challenges.

Tumori·2026

A radiomic approach to non-invasively decode tumor immune microenvironmental features in surgically resected non-small cell lung cancer.

Tumori·2026

When biological complexity demands more than better trial designs.

Tumori·2026

Chimeric thoracodorsal free flap reconstruction for extended circumferential pharyngo-laryngectomy: A case report.

Tumori·2026

Aluminum-based salts: an unorthodox but simple way to treat molluscum contagiosum and cutaneous warts.

F1000Research·2026

Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.

Naunyn-Schmiedeberg's archives of pharmacology·2026

[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

Urologie (Heidelberg, Germany)·2026

ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression.

Oncogene·2026

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

British journal of haematology·2026

Related Experiment Videos

[Adjuvant chemotherapy in breast cancer. International perspective]

Related Concept Videos

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period.

Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.

Survival of carcinoid lung neuroendocrine tumours after surgical resection: A retrospective audit of 633 cases over 26 years.

Analysing workflows in radiation oncology: A process mining approach to identify treatment process challenges.

A radiomic approach to non-invasively decode tumor immune microenvironmental features in surgically resected non-small cell lung cancer.

When biological complexity demands more than better trial designs.

Chimeric thoracodorsal free flap reconstruction for extended circumferential pharyngo-laryngectomy: A case report.

Aluminum-based salts: an unorthodox but simple way to treat molluscum contagiosum and cutaneous warts.

Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.

Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.

[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression.

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Related Experiment Videos

[Adjuvant chemotherapy in breast cancer. International perspective]

Related Concept Videos

Related Articles